Exploring new uses for EGFR inhibitors in certain cancer mutations
Official title: Redefining indications of EGFR inhibitors in cancers that harbor mutant RAS
Funded at Medical College of Wisconsin · NIH-10799827 · Data updated 2026-11-12
This study is looking at how certain cancer treatments might actually help colorectal cancer patients with a specific KRAS mutation, called KRAS G13D, even though it's usually thought that this mutation makes the treatments less effective, and it offers a chance for patients to join trials exploring these new possibilities.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $356,850 |
| NIH project number | 1R01CA276771-01A1 |
| Project ID | NIH-10799827 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are colorectal cancer patients with specific KRAS mutations, particularly those with KRAS G13D.
✕Less likely to help
Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the potential benefits of anti-EGFR agents for colorectal cancer patients with specific KRAS mutations, particularly KRAS G13D. It challenges the traditional understanding that these mutations render patients resistant to such treatments. By employing a novel experimental approach, the study aims to identify additional KRAS mutants that may respond positively to EGFR inhibitors and develop strategies to target resistant cancer cells. Patients may have the opportunity to participate in trials that explore these new treatment avenues.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for colorectal cancer patients who currently have limited effective therapies due to their KRAS mutations.
How similar studies have gone: Previous studies have shown promising results in exploring the efficacy of anti-EGFR agents in patients with KRAS mutations, suggesting that this approach may lead to significant advancements.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Mcfall, Thomas Bradley — Medical College of Wisconsin
- Study coordinator: Mcfall, Thomas Bradley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.